Cargando…

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling

Cardiovascular diseases have become a major clinical burden globally. Heart failure is one of the diseases that commonly emanates from progressive uncontrolled hypertension. This gives rise to the need for a new treatment for the disease. Sacubitril/valsartan is a new drug combination that has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mustafa, Nor Hidayah, Jalil, Juriyati, Zainalabidin, Satirah, Saleh, Mohammed S.M., Asmadi, Ahmad Yusof, Kamisah, Yusof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393311/ https://www.ncbi.nlm.nih.gov/pubmed/36003518 http://dx.doi.org/10.3389/fphar.2022.892460

Ejemplares similares

Genus Parkia: Phytochemical, Medicinal Uses, and Pharmacological Properties
por: Saleh, Mohammed S. M., et al.
Publicado: (2021)

Parkia speciosa Hassk. Empty Pod Extract Prevents Cardiomyocyte Hypertrophy by Inhibiting MAPK and Calcineurin-NFATC3 Signaling Pathways
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Parkia speciosa Hassk. Empty Pod Extract Alleviates Angiotensin II-Induced Cardiomyocyte Hypertrophy in H9c2 Cells by Modulating the Ang II/ROS/NO Axis and MAPK Pathway
por: Siti, Hawa Nordin, et al.
Publicado: (2021)

UPLC-MS-Based Metabolomics Profiling for α-Glucosidase Inhibiting Property of Parkia speciosa Pods
por: Saleh, Mohammed S. M., et al.
Publicado: (2021)

Cardioprotective Properties of Kaempferol: A Review
por: Kamisah, Yusof, et al.
Publicado: (2023)

Rutin Modulates MAPK Pathway Differently from Quercetin in Angiotensin II-Induced H9c2 Cardiomyocyte Hypertrophy
por: Siti, Hawa Nordin, et al.
Publicado: (2021)

New Insights into Molecular Mechanism behind Anti-Cancer Activities of Lycopene
por: Puah, Boon-Peng, et al.
Publicado: (2021)

Angiotensin II Type I Receptor Antagonism Attenuates Nicotine-Induced Cardiac Remodeling, Dysfunction, and Aggravation of Myocardial Ischemia-Reperfusion Injury in Rats
por: Ramalingam, Anand, et al.
Publicado: (2019)

Therapeutic Use and Molecular Aspects of Ivabradine in Cardiac Remodeling: A Review
por: Kamisah, Yusof, et al.
Publicado: (2023)

Data on effect of Sacubitril/valsartan on cardiac Remodelling in diabetic Cardiomyopathy rats
por: Ai, Jiao, et al.
Publicado: (2021)

Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome
por: Wang, Shuangcui, et al.
Publicado: (2023)

Palm Tocotrienol-Rich Fraction Improves Vascular Proatherosclerotic Changes in Hyperhomocysteinemic Rats
por: Norsidah, Ku-Zaifah, et al.
Publicado: (2013)

Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach
por: Iborra-Egea, Oriol, et al.
Publicado: (2017)

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
por: Raj, Pema, et al.
Publicado: (2021)

Roselle attenuates cardiac hypertrophy after myocardial infarction in vivo and in vitro
por: Si, Lislivia-Yiang-Nee, et al.
Publicado: (2019)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction
por: Yang, Pei, et al.
Publicado: (2023)

Editorial: Be positive about the negative in pharmacology: Ethnopharmacology 2022
por: Kamisah, Yusof, et al.
Publicado: (2023)

Inhibitory Effects of Palm Tocotrienol-Rich Fraction Supplementation on Bilirubin-Metabolizing Enzymes in Hyperbilirubinemic Adult Rats
por: Kamisah, Yusof, et al.
Publicado: (2014)

Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats
por: Zhang, Wenchao, et al.
Publicado: (2021)

The Role of Polyphenol in Modulating Associated Genes in Diabetes-Induced Vascular Disorders
por: Mohd Nor, Nor Anizah, et al.
Publicado: (2022)

Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients
por: Yang, Liu, et al.
Publicado: (2022)

Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis
por: Xiang, Qian, et al.
Publicado: (2022)

Short-term effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure
por: Cassano, Velia, et al.
Publicado: (2022)

Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China
por: Wu, Yue, et al.
Publicado: (2020)

Protective Effects of Caesalpinia sappan Linn. and Its Bioactive Compounds on Cardiovascular Organs
por: Syamsunarno, Mas Rizky AA, et al.
Publicado: (2021)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Sacubitril/valsartan, sodium‐glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy
por: Norre, Tobias, et al.
Publicado: (2022)

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
por: Hu, Tianyang, et al.
Publicado: (2023)

Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis
por: Qin, Jianbin, et al.
Publicado: (2022)

Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan
por: Mantegazza, Valentina, et al.
Publicado: (2021)

The Role of PKC-MAPK Signalling Pathways in the Development of Hyperglycemia-Induced Cardiovascular Complications
por: Jubaidi, Fatin Farhana, et al.
Publicado: (2022)

Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy
por: Huang, Hsin‐Ti, et al.
Publicado: (2022)

Sacubitril/valsartan averts post-myocardial infarction ventricular remodeling and preserves heart function
por: Hajra, Adrija, et al.
Publicado: (2019)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan
por: Correale, Michele, et al.
Publicado: (2023)

Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan
por: Fabiani, Iacopo, et al.
Publicado: (2023)

Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice
por: Suo, Ya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hudv28vciqu3lgfcd5m5lkf3ci